Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin

被引:5
|
作者
Elfert, Asem Ahmed [1 ]
机构
[1] Tanta Univ, Fac Med, Dept Trop Med & Infect Dis, Tanta, Egypt
关键词
HCV; Extrahepatic manifestations; Psoriasis; Sofosbuvir; Ribavrin;
D O I
10.1016/j.ajg.2017.09.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
An 18 year old boy attended a dermatology clinic outside our hospital and diagnosed with psoriasis. His skin lesions over both ankles (Fig. 1) did not improve at all with potent local steroids twice for 3 months, then 3 times daily for another 3 months. His dermatologist talked to him about using methotrexate and asked for liver function tests before starting the systemic therapy. His ALT and AST were doubled. The patient came to our Hepatology clinic worried about his elevated liver enzymes. We asked for viral markers. His HCV-Ab was positive, and PCR for HCV-RNA was 650,000 IU/ml. Treatment started with sofosbuvir 400 mg PO once daily plus ribavirin 600 mg at the morning and 400 mg at the evening. After 4 weeks, ALT and AST decreased to normal and PCR for HCV-RNA was <5 IU/ml. All other lab tests were unremarkable. The skin lesions improved markedly (Fig. 2). Now, after 6 months of the end of treatment, sustained virologic response was documented and the skin lesions are almost disappeared without any topical or systemic treatment. © 2017 Pan-Arab Association of Gastroenterology
引用
收藏
页码:234 / 234
页数:1
相关论文
共 50 条
  • [21] Delayed sustained virologic response after treatment of hepatitis C with pegylated interferon and ribavirin
    Yarze, Joseph C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S273 - S273
  • [22] Hepatocellular carcinoma development in Japanese patients with HCV genotype 1 infection who achieved sustained virologic response by ledipasvir/sofosbuvir and protease inhibitor with peginterferon plus ribavirin
    Korenaga, Masaaki
    Izumi, Namiki
    Yokosuka, Osamu
    Takehara, Tetsuo
    Sakamoto, Naoya
    Nishiguchi, Shuhei
    Ikeda, Fusao
    Yanase, Mikio
    Toyoda, Hidenori
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Nakane, Kunio
    Kanto, Tatsuya
    Omata, Masao
    Mizokami, Masashi
    HEPATOLOGY, 2017, 66 : 563A - 564A
  • [23] HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response
    Hamdane, Nourdine
    Juhling, Frank
    Crouchet, Emilie
    El Saghire, Houssein
    Thumann, Christine
    Oudot, Marine A.
    Bandiera, Simonetta
    Saviano, Antonio
    Ponsolles, Clara
    Suarez, Armando Andres Roca
    Li, Shen
    Fujiwara, Naoto
    Ono, Atsushi
    Davidson, Irwin
    Bardeesy, Nabeel
    Schmidl, Christian
    Bock, Christoph
    Schuster, Catherine
    Lupberger, Joachim
    Habersetzer, Francois
    Doffoel, Michel
    Piardi, Tullio
    Sommacale, Daniele
    Imamura, Michio
    Uchida, Takuro
    Ohdan, Hideki
    Aikata, Hiroshi
    Chayama, Kazuaki
    Boldanova, Tujana
    Pessaux, Patrick
    Fuchs, Bryan C.
    Hoshida, Yujin
    Zeisel, Mirjam B.
    Duong, Francois H. T.
    Baumert, Thomas F.
    GASTROENTEROLOGY, 2019, 156 (08) : 2313 - +
  • [24] Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience
    Elfeki, Mohamed A.
    Abou Mrad, Rachel
    Esfeh, Jamak Modaresi
    Zein, Nizar N.
    Eghtesad, Bijan
    Zervos, Xaralambos
    Hanouneh, Ibrahim A.
    O'Shea, Robert
    Carey, William D.
    Alkhouri, Naim
    TRANSPLANTATION, 2017, 101 (05) : 996 - 1000
  • [25] SUSTAINED VIROLOGIC RESPONSE IN THE ANTIVIRAL TREATMENT OF HCV-INFECTION AFTER LIVER TRANSPLANTATION
    Yaroshenko, Ekaterina
    Kornilov, Maxim
    Moysyuk, Yan
    TRANSPLANT INTERNATIONAL, 2013, 26 : 291 - 291
  • [26] HCV Sustained Virologic Response After Only 12 Days of Sofosbuvir plus Ledipasvir Treatment Before Orthotopic Liver Transplantation. A Case Report
    Ferre Aracil, Carlos
    Aguilera Castro, Lara
    Graus Morales, Javier
    Garcia Gonzalez, Miguel
    Lledo Navarro, Jose Luis
    Arocena Aranguren, Carlos
    Rodriguez de Santiago, Enrique
    Gea Rodriguez, Francisco
    Albillos Martinez, Agustin
    TRANSPLANTATION, 2016, 100 : S180 - S180
  • [27] Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b
    Taniyama, Ohki
    Mawatari, Seiichi
    Oda, Kohei
    Tabu, Kazuaki
    Ijuin, Sho
    Kumagai, Kotaro
    Kasai, Ai
    Tashima, Shuzo
    Tamai, Tsutomu
    Moriuchi, Akihiro
    Ido, Akio
    HEPATOLOGY RESEARCH, 2019, 49 (02) : 239 - 243
  • [28] UNDETECTABLE SERUM HCV ANTIGENS AFTER 12 WEEKS OF HCV DAA TREATMENT PREDICTS SUSTAINED VIROLOGIC RESPONSE
    Hu, Ke-Qin
    Cui, Wei
    GASTROENTEROLOGY, 2017, 152 (05) : S1092 - S1092
  • [29] Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in ≥95% Sustained Virologic Response In Patients with HCV Genotype 1, Including Patients with Cirrhosis: the LONESTAR trial
    Lawitz, Eric
    Poordad, Fred
    Hyland, Robert H.
    Ding, Xiao
    Hebner, Christy
    Pang, Phil S.
    Symonds, William T.
    McHutchison, John G.
    Membreno, Fernando E.
    HEPATOLOGY, 2013, 58 : 315A - 316A
  • [30] SUSTAINED VIROLOGIC RESPONSE IS ASSOCIATED WITH WORSE QOL DURING AND IMPROVED QOL AFTER TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN
    von Wagnerl, Michael
    Hofmann, W. Peter
    Teuber, Gerlinde
    Berg, Thomas
    Goeser, Tobias
    Spengler, Ulrich
    Hinrichsen, Holger
    Weidenbach, Hans
    Gerken, Guido
    Manns, Michael P.
    Buggisch, Peter
    Herrmann, Eva
    HEPATOLOGY, 2008, 48 (04) : 886A - 887A